Stock ATORX ALLIGATOR BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

Alligator Bioscience AB Stock

Equities

ATORX

SE0000767188

Biotechnology & Medical Research

Delayed Nasdaq Stockholm
Other stock markets
 06:16:41 2024-04-24 am EDT 		5-day change 1st Jan Change
0.947 SEK -3.76% Intraday chart for Alligator Bioscience AB -9.35% +37.88%
Apr. 05 Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board CI
Mar. 26 Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs CI

Financials

Sales 2024 * 266M 24.49M Sales 2025 * 136M 12.49M Capitalization 746M 68.65M
Net income 2024 * - 0 Net income 2025 * -72M -6.63M EV / Sales 2024 * 1.68 x
Net cash position 2024 * 298M 27.4M Net cash position 2025 * - 0 EV / Sales 2025 * 5.5 x
P/E ratio 2024 *
-1.85 x
P/E ratio 2025 *
-3.09 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.68%
More Fundamentals * Assessed data

Chart Alligator Bioscience AB

Dynamic Chart

Latest news about Alligator Bioscience AB

Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 CI
Transcript : Alligator Bioscience AB, 2023 Earnings Call, Feb 09, 2024
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan MT
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan MT
Alligator Bioscience to Trim Workforce Amid Restructuring Program MT
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation CI
Transcript : Alligator Bioscience AB - Special Call
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer CI
Alligator Bioscience Secures US Patent for Cancer Treatment Antibody MT
Transcript : Alligator Bioscience AB - Analyst/Investor Day
Certain Ordinary Shares of Alligator Bioscience AB are subject to a Lock-Up Agreement Ending on 9-NOV-2023. CI
More news

Latest transcript on Alligator Bioscience AB

Logo Alligator Bioscience AB
Alligator Bioscience AB, 2023 Earnings Call, Feb 09, 2024
More transcripts

Analyst Recommendations on Alligator Bioscience AB

Alligator Bioscience's Pancreatic Cancer Combo Shows Improved Objective Response Rate in Mid-stage Study MT
Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate CI
More recommendations

Press releases Alligator Bioscience AB

Last day of trading in paid subscribed units (Sw. BTU) in Alligator AQ
Alligator publishes outcome in rights issue AQ
Alligator Bioscience Announces Two Presentations on Mitazalimab and ATOR-4066 at the AACR Annual Meeting 2024 AQ
Notice of annual general meeting in Alligator Bioscience AB AQ
BioStock: Alligator Bioscience on the importance of prolonging life AQ
More press releases

News in other languages on Alligator Bioscience AB

Biotechnologies : Alligator boit la tasse
More news

Quotes and Performance

1 day-2.03%
1 week-9.35%
Current month-4.43%
1 month-3.75%
3 months-18.80%
6 months+150.00%
Current year+37.88%
More quotes

Highs and lows

1 week
0.94
Extreme 0.941
1.05
1 month
0.94
Extreme 0.935
1.19
Current year
0.66
Extreme 0.661
1.57
1 year
0.34
Extreme 0.34
1.57
3 years
0.34
Extreme 0.34
7.20
5 years
0.34
Extreme 0.34
26.85
10 years
0.34
Extreme 0.34
40.10
More quotes

Managers and Directors - Alligator Bioscience AB

Managers TitleAgeSince
Søren Bregenholt CEO
 Chief Executive Officer 53 21-05-31
Marie Svensson DFI
 Director of Finance/CFO 60 20-08-31
Sumeet Ambarkhane CTO
 Chief Tech/Sci/R&D Officer 56 22-01-31
Members of the board TitleAgeSince
Graham Dixon BRD
 Director/Board Member 63 19-05-08
Anders Olof Adolf Ekblom CHM
 Chairman 70 16-12-31
Staffan Encrantz BRD
 Director/Board Member 73 22-05-08
More insiders

Quotes

Date Price Change Volume
24-04-24 0.947 -3.76% 944 064
24-04-23 0.984 -1.01% 963,340
24-04-22 0.994 -2.36% 786,608
24-04-19 1.018 -2.12% 597,748
24-04-18 1.04 -0.76% 704,238

Delayed Quote Nasdaq Stockholm, April 24, 2024 at 06:16 am EDT

More quotes

Company Profile

Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Alligator Bioscience AB

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.984 SEK
Average target price
2.3 SEK
Spread / Average Target
+133.74%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALLIGATOR BIOSCIENCE AB Stock Alligator Bioscience AB
+37.88% 68.91M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+48.71% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 12.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 12.59B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ATORX Stock